Billerud expands medical packaging range with MediKraft SealBase

Introducing MediKraft SealBase: Billerud’s latest innovation in medical paper.

 

Billerud has expanded its medical paper portfolio with the introduction of MediKraft SealBase, a surface-treated medical paper. This product broadens Billerud’s offerings in medical paper and will be showcased at the COMPAMED trade fair in Düsseldorf in mid-November.

 

MediKraft SealBase is produced at Billerud’s Skärblacka mill in Sweden using pure virgin fiber and is designed as a base paper for synthetic cold seal coatings. It targets medical applications that do not require a sterile barrier, such as plaster packaging, and may also be compatible with latex-based cold seal coatings. Robert Torstensson, Vice President of Billerud’s Business Area Paper, noted, “MediKraft SealBase demonstrates our commitment to the medical segment and providing innovative solutions to our customers.”

 

Billerud emphasizes the product’s safety and manufacturing standards, achieved through integrated pulp production and stringent quality control. The company does not use Optical Brightening Agents (OBAs) in MediKraft SealBase, and quality is monitored using Web Inspection Systems and bioburden testing. The paper has been tested for compatibility with various sterilization methods, including electron beam, gamma, ethylene oxide, and steam sterilization.

 

The product also aligns with Billerud’s environmental goals. “MediKraft SealBase offers a competitive edge through our advanced sustainability credentials,” Torstensson said. Billerud’s commitment to transparency includes publishing Environmental Product Declarations (EPDs) for nearly all of its medical paper products, with plans to expand this practice.

 

Billerud brings over five decades of experience in medical paper production, supplying two main lines: SteriKraft, which provides microbial barrier properties for sterilization, and MediKraft, suitable for non-sterile applications like glove inner wrapping and plaster packaging.